AIM ImmunoTechAIM
Market Cap: $18.7M
About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Employees: 28
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
60% more capital invested
Capital invested by funds: $1.97M [Q1] → $3.15M (+$1.18M) [Q2]
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
9% more funds holding
Funds holding: 33 [Q1] → 36 (+3) [Q2]
6.22% more ownership
Funds ownership: 8.56% [Q1] → 14.78% (+6.22%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Ascendiant Capital Edward Woo 25% 1-year accuracy 10 / 40 met price target | 1,424%upside $5 | Buy Maintained | 3 Sept 2024 |
Financial journalist opinion
Based on 5 articles about AIM published over the past 30 days